- Home
- TZOO vs GLSI Comparison
TZOO vs GLSI Comparison
Compare TZOO & GLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TZOO
- GLSI
- Stock Information
- Founded
- TZOO 1998
- GLSI 2006
- Country
- TZOO United States
- GLSI United States
- Employees
- TZOO N/A
- GLSI N/A
- Industry
- TZOO Advertising
- GLSI Biotechnology: Pharmaceutical Preparations
- Sector
- TZOO Consumer Discretionary
- GLSI Health Care
- Exchange
- TZOO Nasdaq
- GLSI Nasdaq
- Market Cap
- TZOO 136.1M
- GLSI 134.6M
- IPO Year
- TZOO 2002
- GLSI 2020
- Fundamental
- Price
- TZOO $10.80
- GLSI $11.57
- Analyst Decision
- TZOO Strong Buy
- GLSI Strong Buy
- Analyst Count
- TZOO 4
- GLSI 1
- Target Price
- TZOO $23.50
- GLSI $39.00
- AVG Volume (30 Days)
- TZOO 179.3K
- GLSI 85.4K
- Earning Date
- TZOO 07-23-2025
- GLSI 08-13-2025
- Dividend Yield
- TZOO N/A
- GLSI N/A
- EPS Growth
- TZOO N/A
- GLSI N/A
- EPS
- TZOO 0.90
- GLSI N/A
- Revenue
- TZOO $87,822,000.00
- GLSI N/A
- Revenue This Year
- TZOO $16.97
- GLSI N/A
- Revenue Next Year
- TZOO $23.72
- GLSI N/A
- P/E Ratio
- TZOO $11.99
- GLSI N/A
- Revenue Growth
- TZOO 3.47
- GLSI N/A
- 52 Week Low
- TZOO $7.81
- GLSI $8.06
- 52 Week High
- TZOO $24.85
- GLSI $17.00
- Technical
- Relative Strength Index (RSI)
- TZOO 31.88
- GLSI 60.72
- Support Level
- TZOO $12.73
- GLSI $11.06
- Resistance Level
- TZOO $12.87
- GLSI $12.54
- Average True Range (ATR)
- TZOO 0.59
- GLSI 0.75
- MACD
- TZOO -0.23
- GLSI 0.07
- Stochastic Oscillator
- TZOO 1.75
- GLSI 61.81
About TZOO Travelzoo
Travelzoo acts as a publisher of travel and entertainment offers. It operates in four segments. Travelzoo North America segment, which is the key revenue driver, consists of operations in Canada and the U.S.; Travelzoo Europe segment consists of operations in France, Germany, Spain, and the U.K.; Jack's Flight Club segment consists of subscription revenue from premium members to access and receive flight deals from Jack's Flight Club via email or via Android or Apple mobile applications; and New Initiatives consists of Travelzoo's licensing activities in Asia Pacific territories. It derives its revenue through advertising fees including listing fees paid by travel, entertainment, and local businesses to advertise their offers on the company's media properties.
About GLSI Greenwich LifeSciences Inc.
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.